|
Guideline or local working group recommendation
|
Number of respondents consulting for diagnosis, n (%)a
|
|---|
| |
France
|
Germany
|
Italy
|
Spain
|
UK
|
Total
|
|---|
|
N = 15
|
N = 15
|
N = 15
|
N = 15
|
N = 15
|
N = 75
|
|---|
|
ASH/ASCO, US
|
6 (40)
|
2 (13)
|
10 (67)
|
5 (33)
|
3 (20)
|
26 (35)
|
|
EWALL, Europe
|
6 (40)
|
1 (7)
|
3 (20)
|
2 (13)
|
4 (27)
|
16 (21)
|
|
NCCN, US
|
3 (20)
| |
7 (47)
|
4 (27)
| |
14 (19)
|
|
GMALL, Germany
|
1 (7)
|
8 (53)
|
1 (7)
|
1 (7)
| |
11 (15)
|
|
GIMEMA, Italy
| | |
10 (67)
| | |
10 (13)
|
|
PETHEMA, Spain
| | | |
9 (60)
| |
9 (12)
|
|
Othersb
|
3 (20)
| | | |
1 (7)
|
4 (5)
|
- aRespondents could select multiple guidelines
- bThe following guidelines and/or local working group recommendations were consulted by one respondent for diagnosis: HAS, France; Onco LR, France; GELA, France; BCSH, UK
- ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for Standards in Haematology; EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group of the Adult Lymphoma); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology
